子宮注射"粒細胞集落刺激因子"（G - CSF），兩天後植入囊胚期的胚胎，是妳試管嬰兒懷孕成功最佳選擇！！！ 妳做試管嬰兒一直都失敗， 是因為子宮內膜薄胚胎沒辦法著床或一直流產的病人有福音了， 我們可以在取卵後三天在子宮腔注射"粒細胞集落刺激因子"（G - CSF）， 在兩天之後植入胚胎，它可以在48小時之內瞬間增加子宮內膜的厚度， 根據美國紐約市的兩家試管嬰兒中心研究發現，四個病人以前都因為子宮內膜薄而試管嬰兒失敗沒辦法著床， 經過使用"粒細胞集落刺激因子"灌注子宮這四個人全部懷孕， 方法是：禮拜一
2013.08.31
子宮注射"粒細胞集落刺激因子"（G - CSF），兩天後植入囊胚期的胚胎，
妳做試管嬰兒一直都失敗，
是因為子宮內膜薄胚胎沒辦法著床或一直流產的病人有福音了，
我們可以在取卵後三天在子宮腔注射"粒細胞集落刺激因子"（G - CSF），
在兩天之後植入胚胎，
根據美國紐約市的兩家試管嬰兒中心研究發現，
經過使用"粒細胞集落刺激因子"灌注子宮這四個人全部懷孕，
方法是：禮拜一取卵、禮拜四子宮注射"粒細胞集落刺激因子"（G - CSF），兩天後植入囊胚期的胚胎，
反敗為勝，可戲劇化增加試管嬰兒成功率！把"粒細胞集落刺激因子
子宮內膜有什麼方法可以變厚呢? 一份 Human Reproduction 人類生殖期刊的研究報告
美國紐約市的中心人類生殖（CHR）的紐約州和生育第二個中心N
研究人員從紐約市的中心人類生殖（CHR）的紐約州和生育第二個
子宮內膜變厚要用荷爾蒙，以及血管刺激因子的藥物。
這個是美國紐約方面的研究，至於如果妳要讓子宮內膜變厚，並不需
戲劇化增加試管嬰兒成功的～G－CSF
有什麼新的試管嬰兒技術？
你好：GCSF是針對子宮內膜薄，而試管嬰兒失敗的個案，請看以
GCSF目前在美國食品藥物管理局（FDA）是允許用在病人身上
戲劇化增加試管嬰兒成功的～G－CSF～
G - CSF的治療可改善IVF週期中子宮內膜不足
在體外授精（IVF）的週期，治療的藥物稱為粒細胞集落刺激因子
的G - CSF是一種細胞因子（蛋白質分子之間的溝通，以促進細胞）已被
研究人員從紐約市的中心人類生殖（CHR）的紐約州和生育第二個
在大約 1％的IVF週期，子宮內膜薄停留太成功植入胚胎，即使治療。在
“傳統的治療方法的不足，子宮內膜有參差不齊的成功最好的。無G - CSF的灌注，這些患者中，有可能，就不會達到胚胎移植，”解釋
“療效的G - CSF的改善子宮內膜，並有可能懷孕率在一般情況下，仍然需要在
博元婦產科不孕症試管嬰兒中心:蔡鋒博,陳昭雯醫師
原文：
G-CSF treatment improves inadequate endometrium during IVF cycles
24. February 2011 03:26
During in vitro fertilization (IVF) cycles, treatment with a medication calledgranulocyte-colony stimulating factor (G-CSF) significantly improves inadequate endometrium (lining of theuterus), according to a report published electronically on February 15 in Fertility and Sterility - the official journal of the American Society for Reproductive Medicine (ASRM). The reported case series also suggests that G-CSF treatment may, in general, improve IVF pregnancy chances.
G-CSF is a cytokine (protein molecules that facilitate communication between cells) that has already been FDA approved for other clinical indications.
Researchers from New York City-based Center for Human Reproduction (CHR) and a second NY fertility center reported on four women with highly inadequate endometrium, unresponsive to conventional treatments and facing IVF cycle cancellation. In all four cases, endometrial perfusion of G-CSF expanded the endometrium to a minimal thickness of 7mm within approximately 48 hours, allowing for embryo transfer. Surprisingly, all four patients also conceived.
In approximately 1% of all IVF cycles, the endometrium stays too thin for embryos to successfully implant, even with treatment. In such IVF cycles, patients and physicians face two poor options: they either accept lower pregnancy chances and transfer embryos despite inadequate endometrium, or they can cancel the embryo transfer and freeze all embryos in hope of better future cycles. Unfortunately, women with inadequate endometrium often show inadequate endometrium again in future cycles. This situation was demonstrated by two patients in this reported case series with histories of repeat IVF failures due to thin endometrium.
"Conventional treatments for inadequate endometrium have had spotty success at best. Without G-CSF perfusion, these patients, likely, would not have reached embryo transfer," explains David Barad, MD, Director of Clinical ART at CHR and one of the senior authors of the report. "That all of them also conceived was a big surprise, and is, of course, quite remarkable."
"The efficacy of G-CSF in improving endometrium, and possibly pregnancy rates in general, still needs to be confirmed in randomized controlled trials," adds Norbert Gleicher, MD, lead author of the report and Medical Director of CHR. "Indeed, we already started two such trials to test both hypotheses; but until first results become available later in 2011, we caution against over-interpreting results of this small pilot study."
SOURCE Center for Human Reproduction
子宮內膜變厚要用荷爾蒙，以及血管刺激因子的藥物。
這個是美國紐約方面的研究，至於如果妳要讓子宮內膜變厚，並不需
戲劇化增加試管嬰兒成功的～G－CSF
有什麼新的試管嬰兒技術？
你好：GCSF是針對子宮內膜薄，而試管嬰兒失敗的個案，請看以
GCSF目前在美國食品藥物管理局（FDA）是允許用在病人身上
戲劇化增加試管嬰兒成功的～G－CSF～
G - CSF的治療可改善IVF週期中子宮內膜不足
在體外授精（IVF）的週期，治療的藥物稱為粒細胞集落刺激因子
的G - CSF是一種細胞因子（蛋白質分子之間的溝通，以促進細胞）已被
研究人員從紐約市的中心人類生殖（CHR）的紐約州和生育第二個
在大約 1％的IVF週期，子宮內膜薄停留太成功植入胚胎，即使治療。在
“傳統的治療方法的不足，子宮內膜有參差不齊的成功最好的。無G - CSF的灌注，這些患者中，有可能，就不會達到胚胎移植，”解釋
“療效的G - CSF的改善子宮內膜，並有可能懷孕率在一般情況下，仍然需要在
博元婦產科不孕症試管嬰兒中心:蔡鋒博,陳昭雯醫師
原文：
G-CSF treatment improves inadequate endometrium during IVF cycles
24. February 2011 03:26
During in vitro fertilization (IVF) cycles, treatment with a medication calledgranulocyte-colony stimulating factor (G-CSF) significantly improves inadequate endometrium (lining of theuterus), according to a report published electronically on February 15 in Fertility and Sterility - the official journal of the American Society for Reproductive Medicine (ASRM). The reported case series also suggests that G-CSF treatment may, in general, improve IVF pregnancy chances.
G-CSF is a cytokine (protein molecules that facilitate communication between cells) that has already been FDA approved for other clinical indications.
Researchers from New York City-based Center for Human Reproduction (CHR) and a second NY fertility center reported on four women with highly inadequate endometrium, unresponsive to conventional treatments and facing IVF cycle cancellation. In all four cases, endometrial perfusion of G-CSF expanded the endometrium to a minimal thickness of 7mm within approximately 48 hours, allowing for embryo transfer. Surprisingly, all four patients also conceived.
In approximately 1% of all IVF cycles, the endometrium stays too thin for embryos to successfully implant, even with treatment. In such IVF cycles, patients and physicians face two poor options: they either accept lower pregnancy chances and transfer embryos despite inadequate endometrium, or they can cancel the embryo transfer and freeze all embryos in hope of better future cycles. Unfortunately, women with inadequate endometrium often show inadequate endometrium again in future cycles. This situation was demonstrated by two patients in this reported case series with histories of repeat IVF failures due to thin endometrium.
"Conventional treatments for inadequate endometrium have had spotty success at best. Without G-CSF perfusion, these patients, likely, would not have reached embryo transfer," explains David Barad, MD, Director of Clinical ART at CHR and one of the senior authors of the report. "That all of them also conceived was a big surprise, and is, of course, quite remarkable."
"The efficacy of G-CSF in improving endometrium, and possibly pregnancy rates in general, still needs to be confirmed in randomized controlled trials," adds Norbert Gleicher, MD, lead author of the report and Medical Director of CHR. "Indeed, we already started two such trials to test both hypotheses; but until first results become available later in 2011, we caution against over-interpreting results of this small pilot study."
SOURCE Center for Human Reproduction
不孕症諮詢電話：04-726 0678 轉 120、123 
不孕症傳真專線：04-722 5626 
信箱：